{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:16:09Z","timestamp":1793643369437,"version":"4.5.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-025-05091-8","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T15:51:51Z","timestamp":1740412311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Progressive multifocal leukoencephalopathy in rheumatoid arthritis and biological therapies: a case report and review of the literature"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9211-5504","authenticated-orcid":false,"given":"Barbara","family":"Bergmans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin","family":"Roks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e8ne","family":"van Puijenbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Murk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"5091_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev-pathol-020712-164018","volume":"8","author":"S Gheuens","year":"2013","unstructured":"Gheuens S, Wuthrich C, Koralnik IJ. Progressive multifocal leukoencephalopathy: why gray and white matter. Annu Rev Pathol. 2013;8:189\u2013215.","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"5091_CR2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/brain\/awac237","volume":"146","author":"M Joly","year":"2023","unstructured":"Joly M, Conte C, Cazanave C, Le Moing V, Tattevin P, Delobel P, et al. Progressive multifocal leukoencephalopathy: epidemiology and spectrum of predisposing conditions. Brain. 2023;146(1):349\u201358.","journal-title":"Brain"},{"key":"5091_CR3","doi-asserted-by":"publisher","first-page":"1208155","DOI":"10.3389\/fcimb.2023.1208155","volume":"13","author":"R Jiang","year":"2023","unstructured":"Jiang R, Song Z, Liu L, Mei X, Sun J, Qi T, et al. Survival and prognostic factors of progressive multifocal leukoencephalopathy in people living with HIV in modern ART era. Front Cell Infect Microbiol. 2023;13:1208155.","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"5091_CR4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/ana.10827","volume":"55","author":"A d\u2019Arminio Monforte","year":"2004","unstructured":"d\u2019Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol. 2004;55(3):320\u20138.","journal-title":"Ann Neurol"},{"issue":"20","key":"5091_CR5","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood. 2009;113(20):4834\u201340.","journal-title":"Blood"},{"issue":"2","key":"5091_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.idc.2020.02.007","volume":"34","author":"A Multani","year":"2020","unstructured":"Multani A, Ho DY. JC polyomavirus infection potentiated by biologics. Infect Dis Clin North Am. 2020;34(2):359\u201388.","journal-title":"Infect Dis Clin North Am"},{"issue":"15 Supplement","key":"5091_CR7","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1212\/WNL.94.15_supplement.2815","volume":"94","author":"G Giovannoni","year":"2020","unstructured":"Giovannoni G, Kappos L, Berger J, Cutter G, Fox R, Wiendl H, et al. Updated incidence of natalizumab-associated progressive multifocal leukoencephalopathy (PML) and its relationship with natalizumab exposure over time (2815). Neurology. 2020;94(15 Supplement):2815.","journal-title":"Neurology"},{"issue":"4","key":"5091_CR8","first-page":"e14764","volume":"13","author":"G Vivekanandan","year":"2021","unstructured":"Vivekanandan G, Abubacker AP, Myneni R, Chawla HV, Iqbal A, Grewal A, et al. Risk of progressive multifocal leukoencephalopathy in multiple sclerosis patient treated with natalizumab: a systematic review. Cureus. 2021;13(4):e14764.","journal-title":"Cureus"},{"issue":"20","key":"5091_CR9","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870\u201380.","journal-title":"N Engl J Med"},{"issue":"2","key":"5091_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/1352458511435105","volume":"18","author":"PS S\u00f8rensen","year":"2012","unstructured":"S\u00f8rensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012;18(2):143\u201352.","journal-title":"Mult Scler"},{"issue":"8","key":"5091_CR11","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","volume":"10","author":"KR Carson","year":"2009","unstructured":"Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) project. Lancet Oncol. 2009;10(8):816\u201324.","journal-title":"Lancet Oncol"},{"issue":"4","key":"5091_CR12","doi-asserted-by":"publisher","first-page":"107327481772990","DOI":"10.1177\/1073274817729901","volume":"24","author":"C Bohra","year":"2017","unstructured":"Bohra C, Sokol L, Dalia S. Progressive multifocal leukoencephalopathy and monoclonal antibodies: a review. Cancer Control. 2017;24(4):1073274817729901.","journal-title":"Cancer Control"},{"issue":"9","key":"5091_CR13","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","volume":"68","author":"DB Clifford","year":"2011","unstructured":"Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011;68(9):1156\u201364.","journal-title":"Arch Neurol"},{"issue":"12","key":"5091_CR14","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1002\/art.24966","volume":"60","author":"ES Molloy","year":"2009","unstructured":"Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 2009;60(12):3761\u20135.","journal-title":"Arthritis Rheum"},{"key":"5091_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12216945","author":"E Emmanouilidou","year":"2023","unstructured":"Emmanouilidou E, Kosmara D, Papadaki E, Mastorodemos V, Constantoulakis P, Repa A, et al. Progressive multifocal leukoencephalopathy in systemic lupus erythematosus: a consequence of patient-intrinsic or -extrinsic factors? J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12216945.","journal-title":"J Clin Med"},{"issue":"39","key":"5091_CR16","doi-asserted-by":"publisher","first-page":"e35265","DOI":"10.1097\/MD.0000000000035265","volume":"102","author":"V Jain","year":"2023","unstructured":"Jain V, Branstetter H, Savaram S, Vasquez M, Swords G, Aghili-Mehrizi S, et al. Progressive multifocal leukoencephalopathy without overt immunosuppression. Medicine. 2023;102(39):e35265.","journal-title":"Medicine"},{"issue":"6","key":"5091_CR17","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1212\/WNL.0000000000004926","volume":"90","author":"E Iacobaeus","year":"2018","unstructured":"Iacobaeus E, Burkill S, Bahmanyar S, Hakim R, Bystrom C, Fored M, et al. The national incidence of PML in Sweden, 1988\u20132013. Neurology. 2018;90(6):e498\u2013506.","journal-title":"Neurology"},{"issue":"8","key":"5091_CR18","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1128\/JCM.43.8.4175-4177.2005","volume":"43","author":"A Marzocchetti","year":"2005","unstructured":"Marzocchetti A, Di Giambenedetto S, Cingolani A, Ammassari A, Cauda R, De Luca A. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol. 2005;43(8):4175\u20137.","journal-title":"J Clin Microbiol"},{"key":"5091_CR19","unstructured":"Miskin DP, Ngo LH, Koralnik IJ. Diagnostic delay in progressive multifocal leukoencephalopathy. (2328\u20139503 (Print))."},{"issue":"11","key":"5091_CR20","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.jfma.2019.05.021","volume":"118","author":"CF Cheng","year":"2019","unstructured":"Cheng CF, Su JJ, Chen YF, Lin YC, Huang YM, Li KJ. Progressive multifocal leukoencephalopathy in a 27-year-old lady with systemic lupus erythematosus\u2014rheumatoid arthritis overlap syndrome. J Formos Med Assoc. 2019;118(11):1560\u20135.","journal-title":"J Formos Med Assoc"},{"issue":"11","key":"5091_CR21","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1002\/art.27687","volume":"62","author":"D Kumar","year":"2010","unstructured":"Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum. 2010;62(11):3191\u20135.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"5091_CR22","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1136\/annrheumdis-2013-204978","volume":"73","author":"M Ray","year":"2014","unstructured":"Ray M, Curtis JR, Baddley JW. A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab. Ann Rheum Dis. 2014;73(7):1429\u201330.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5091_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.rx.2019.06.003","volume":"62","author":"P L\u00f3pez Sala","year":"2020","unstructured":"L\u00f3pez Sala P, Alberdi Aldasoro N, Zelaya Huerta MV, Bacaicoa Saralegui MC, Cabada GT. Cortical hypointensity in T2-weighted gradient-echo sequences in patients with progressive multifocal leukoencephalopathy. Radiologia. 2020;62(1):59\u201366.","journal-title":"Radiologia"},{"issue":"4","key":"5091_CR24","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/acr.21564","volume":"64","author":"A Bharat","year":"2012","unstructured":"Bharat A, Xie F, Baddley JW, Beukelman T, Chen L, Calabrese L, et al. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res. 2012;64(4):612\u20135.","journal-title":"Arthritis Care Res"},{"key":"5091_CR25","first-page":"643216","volume":"2015","author":"MA Babi","year":"2015","unstructured":"Babi MA, Pendlebury W, Braff S, Waheed W. JC virus PCR detection is not infallible: a fulminant case of progressive multifocal leukoencephalopathy with false-negative cerebrospinal fluid studies despite progressive clinical course and radiological findings. Case Rep Neurol Med. 2015;2015:643216.","journal-title":"Case Rep Neurol Med"},{"issue":"1","key":"5091_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3109\/s10165-006-0530-2","volume":"17","author":"M Yamamoto","year":"2007","unstructured":"Yamamoto M, Takahashi H, Wakasugi H, Sukawa Y, Saito M, Suzuki C, et al. Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis. Mod Rheumatol. 2007;17(1):72\u20134.","journal-title":"Mod Rheumatol"},{"issue":"15","key":"5091_CR27","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.2169\/internalmedicine.48.1926","volume":"48","author":"K Kobayashi","year":"2009","unstructured":"Kobayashi K, Okamoto Y, Inoue H, Usui T, Ihara M, Kawamata J, et al. Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA). Intern Med. 2009;48(15):1307\u20139.","journal-title":"Intern Med"},{"issue":"1","key":"5091_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s13365-021-01028-1","volume":"28","author":"S Darcy","year":"2022","unstructured":"Darcy S, Alex M, McCarthy A, O\u2019Dowd S. Pembrolizumab treatment of inflammatory progressive multifocal leukoencephalopathy: a report of two cases. J NeuroVirol. 2022;28(1):145\u201350.","journal-title":"J NeuroVirol"},{"issue":"10","key":"5091_CR29","first-page":"e10888","volume":"12","author":"M Guduru","year":"2020","unstructured":"Guduru M, Bendi VS, Bebawy MS, Bande D, Matta A. Posterior fossa progressive multifocal leukoencephalopathy secondary to rituximab. Cureus. 2020;12(10):e10888.","journal-title":"Cureus"},{"issue":"3","key":"5091_CR30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4997\/jrcpe.2016.305","volume":"46","author":"L Sammut","year":"2016","unstructured":"Sammut L, Wallis D, Holroyd C. Progressive multifocal leukoencephalopathy associated with infliximab. J R Coll Physicians Edinb. 2016;46(3):163\u20135.","journal-title":"J R Coll Physicians Edinb"},{"issue":"16","key":"5091_CR31","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.2169\/internalmedicine.4431-20","volume":"59","author":"M Anada","year":"2020","unstructured":"Anada M, Tohyama M, Oda Y, Kamoshima Y, Amino I, Nakano F, et al. Progressive multifocal leukoencephalopathy during tocilizumab treatment for rheumatoid arthritis. Intern Med. 2020;59(16):2053\u20139.","journal-title":"Intern Med"},{"issue":"11","key":"5091_CR32","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1002\/art.24906","volume":"60","author":"RM Fleischmann","year":"2009","unstructured":"Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum. 2009;60(11):3225\u20138.","journal-title":"Arthritis Rheum"},{"issue":"18","key":"5091_CR33","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.2169\/internalmedicine.2570-18","volume":"58","author":"Y Nosaki","year":"2019","unstructured":"Nosaki Y, Ohyama K, Watanabe M, Yokoi T, Nakamichi K, Saijo M, et al. Simultaneous development of progressive multifocal leukoencephalopathy and cryptococcal meningitis during methotrexate and infliximab treatment. Intern Med. 2019;58(18):2703\u20139.","journal-title":"Intern Med"},{"issue":"3","key":"5091_CR34","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s13365-018-0615-7","volume":"24","author":"JR Berger","year":"2018","unstructured":"Berger JR, Malik V, Lacey S, Brunetta P, Lehane PB. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. J Neurovirol. 2018;24(3):323\u201331.","journal-title":"J Neurovirol"},{"issue":"9","key":"5091_CR35","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1002\/art.34468","volume":"64","author":"ES Molloy","year":"2012","unstructured":"Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum. 2012;64(9):3043\u201351.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"5091_CR36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ana.22128","volume":"68","author":"L Gorelik","year":"2010","unstructured":"Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68(3):295\u2013303.","journal-title":"Ann Neurol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05091-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-025-05091-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05091-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T15:51:54Z","timestamp":1740412314000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05091-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5091"],"URL":"https:\/\/doi.org\/10.1186\/s13256-025-05091-8","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"15 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this case report was a retrospective study, ethics approval or consent to participate were not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s next-of-kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}